ALKEM · NSE
Alkem Laboratories Limited
₹5,185
+0.78% (+₹40)
Prev. close
₹5,145
Volume
69,594
Delivery %
41.5%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Alkem Laboratories futures, recommending a buy in the ₹5,300-5,330 range with targets of ₹5,450-5,550 and a s…” | Jay ThakkarICICI Securities | Alkem Laboratories | MISS | |
| “Recommends buying Alkem Laboratories Futures in the range of ₹5,560-5,580, with a stop loss at ₹5,450 and targets of ₹5,…” | Jay ThakkarICICI Securities | Alkem Laboratories | MISS | |
| “ICICI Securities recommends buying Alkem Laboratories with a target price of ₹6,400. The call is based on the company's …” | ICICI Securities AnalysisICICI Securities | Alkem Laboratories | MISS | |
| “Bullish on Alkem Laboratories for the next 2-3 weeks, with target prices of ₹5,800 and ₹6,000. The stock broke out from …” | Vishnu Kant UpadhyayMaster Capital Services | Alkem Laboratories | MISS | |
| “Maintains an 'Add' call on Alkem Laboratories with a revised target price of ₹5,900, down from ₹5,920. The brokerage ant…” | ICICI Securities AnalysisICICI Securities | Alkem Laboratories Ltd | MISS | |
| “Jefferies maintains an 'Underperform' rating on Alkem Labs, cutting its target price to ₹4,460. The Q4 performance misse…” | Jefferies AnalysisJefferies | Alkem Laboratories Ltd | MISS | |
| “Nomura maintains a 'Buy' rating on Alkem Labs with a target price of ₹5,430. Q4 sales were in line, though EBITDA and PA…” | Nomura AnalysisNomura Global Markets Research | Alkem Laboratories Ltd | HIT | |
| “Bullish on Alkem Laboratories Ltd, recommending a buy with a target range of ₹5,500–5,704 and a stop loss at ₹4,920 for …” | Gajendra PrabhuHDFC Securities | Alkem Laboratories Ltd | MISS | |
| “Recommends buying Alkem Laboratories Ltd in the near term with a target of ₹5,704 and a stop-loss at ₹4,920. The stock h…” | Vinay RajaniHDFC Securities | Alkem Laboratories Ltd | MISS | |
| “HDFC Securities recommends adding Alkem Laboratories shares with a target price of Rs 5,700, up from the current market …” | HDFC SecuritiesHDFC Securities | Alkem Laboratories | HIT | |
| “Bullish on Alkem Laboratories with a target of ₹6,325 and a stop loss at ₹6,150, suggesting a short-term buy.” | Kunal BothraIndependent | Alkem Laboratories | PENDING |
Fundamentals
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Basudeo Narian Singh
Headquarters
Mumbai
Employees
19,346
Website
alkemlabs.comExchange
View on NSE ↗Key stats
Market cap
₹61,791.19 Cr
P/E ratio (TTM)
29.1
Dividend yield
0.38%
EPS (TTM)
₹177.65
Beta (1Y · daily vs NIFTY 50)
0.68
Beta (5Y · monthly vs NIFTY 50)
0.76
Shares float
4.61 Cr
EPS · quarter ended Jun 2026
₹43.49
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹10,796.84 Cr | ₹11,815.34 Cr | ₹12,978.42 Cr | ₹13,458.26 Cr | ₹15,295.62 Cr | |
| ₹8,937.60 Cr | ₹10,407.59 Cr | ₹10,833.80 Cr | ₹10,931.23 Cr | ₹12,249.90 Cr | |
| ₹1,844.28 Cr | ₹1,304.77 Cr | ₹2,023.13 Cr | ₹2,527.03 Cr | ₹2,870.89 Cr | |
3 Profit before exceptional items and tax (1) - (2) | ₹1,859.24 Cr | ₹1,407.75 Cr | ₹2,144.62 Cr | ₹2,527.03 Cr | ₹3,045.72 Cr |
4 Exceptional items | ₹-14.96 Cr | ₹-102.98 Cr | ₹-121.49 Cr | — | ₹-174.83 Cr |
| ₹163.96 Cr | ₹297.96 Cr | ₹211.67 Cr | ₹311.03 Cr | ₹517.76 Cr | |
8 Profit attributable to Non-Controlling Interest | ₹34.70 Cr | ₹22.64 Cr | — | — | — |
9 Profit attributable to Owners of the Company (7) - (8) | ₹1,645.62 Cr | ₹984.17 Cr | — | — | — |
7 Share in loss after tax of associate | — | — | — | ₹-62.00 L | ₹-1.97 Cr |
8 Profit for the year (5) - (6) + (7) | ₹1,680.32 Cr | ₹1,006.81 Cr | ₹1,811.46 Cr | ₹2,215.38 Cr | ₹2,351.16 Cr |
(a) (i) Items that will not be reclassified subsequently to profit or loss | ₹-9.09 Cr | ₹-4.87 Cr | ₹-9.34 Cr | ₹-21.81 Cr | ₹12.09 Cr |
(ii) Income tax relating to items that will not be reclassified to profit or loss | ₹3.32 Cr | ₹1.61 Cr | ₹2.98 Cr | ₹7.21 Cr | ₹-3.81 Cr |
(b) (i) Items that will be reclassified to profit or loss | ₹39.91 Cr | ₹118.16 Cr | ₹26.40 Cr | ₹34.32 Cr | ₹175.51 Cr |
11 Other Comprehensive Income/(Loss) attributable to Non-Controlling Interest | ₹-41.00 L | ₹-41.00 L | — | — | — |
12 Other Comprehensive Income/(Loss) attributable to Owners of the Company (10) - (11) | ₹34.55 Cr | ₹115.31 Cr | — | — | — |
14 Total Comprehensive Income/(Loss) attributable to Non-Controlling Interest (8) + (11) | ₹34.29 Cr | ₹22.23 Cr | — | — | — |
15 Total Comprehensive Income/(Loss) attributable to Owners of the Company (13) - (14) | ₹1,680.17 Cr | ₹1,099.48 Cr | — | — | — |
Total other comprehensive income for the year (net of tax) | ₹34.14 Cr | ₹114.90 Cr | ₹20.04 Cr | ₹19.72 Cr | ₹183.79 Cr |
10 Total comprehensive income for the year (8) + (9) | ₹1,714.46 Cr | ₹1,121.71 Cr | ₹1,831.50 Cr | ₹2,235.10 Cr | ₹2,534.95 Cr |
Owners of the Company | — | — | ₹1,795.77 Cr | ₹2,165.48 Cr | ₹2,301.80 Cr |
Non-controlling interests | — | — | ₹15.69 Cr | ₹49.90 Cr | ₹49.36 Cr |
Owners of the Company | — | — | ₹20.65 Cr | ₹20.75 Cr | ₹182.38 Cr |
Non-controlling interests | — | — | ₹-61.00 L | ₹-1.03 Cr | ₹1.41 Cr |
Owners of the Company | — | — | ₹1,816.42 Cr | ₹2,186.23 Cr | ₹2,484.18 Cr |
Non-controlling interests | — | — | ₹15.08 Cr | ₹48.87 Cr | ₹50.77 Cr |
14 Basic and diluted earnings per share | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹11,519.26 Cr | ₹14,069.19 Cr | ₹13,756.65 Cr | ₹15,574.90 Cr | ₹17,691.10 Cr | ₹20,872.97 Cr | |
| ₹11,519.26 Cr | ₹14,069.19 Cr | ₹13,756.65 Cr | ₹15,574.90 Cr | ₹17,691.10 Cr | ₹20,872.97 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹1,111.02 Cr | ₹1,682.50 Cr | ₹1,948.07 Cr | ₹1,912.84 Cr | ₹1,963.03 Cr | |
| ₹-1,435.13 Cr | ₹112.84 Cr | ₹-1,008.50 Cr | ₹-1,298.76 Cr | ₹-1,667.21 Cr | |
| ₹55.46 Cr | ₹34.52 Cr | ₹-205.44 Cr | ₹-196.91 Cr | ₹-207.58 Cr | |
E Cash Cash Equivalents as at the beginning of the year (net of loans repayable on demand from banks) | ₹174.22 Cr | ₹232.18 Cr | ₹273.80 Cr | ₹66.31 Cr | ₹-120.09 Cr |
Add/Less: Effect of exchange difference on foreign currency cash and cash equivalents | ₹2.50 Cr | ₹7.10 Cr | ₹-2.05 Cr | ₹10.51 Cr | ₹-14.46 Cr |
Cash and cash equivalents as at end of the year (D+E) (Refer Note 3.9) | ₹232.18 Cr | ₹273.80 Cr | — | — | — |
F Cash Cash Equivalents as at the end of the year (net of loans repayable on demand from banks) (D+E) (Refer Note 3 below) | — | — | ₹66.31 Cr | ₹-120.09 Cr | ₹-342.13 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22–Jun 23(4Q) | Sep 23–Mar 24(3Q) | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25–Mar 26(3Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 58.84% | 57.13% | 57.14% | 57.16% | 56.74% | 56.38% | 55.66% | 55.13% | 53.04% | 51.20% | 49.70% |
| Public | 41.16% | 42.87% | 42.86% | 42.84% | 43.26% | 43.62% | 44.34% | 44.87% | 46.96% | 48.80% | 50.30% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Alkem Laboratories Limited | ₹61,791.19 Cr | ₹5,216.5 | 29.1 | 4.47 | 16.7% | 0.15 | +13.5% | -7.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.